Clinical and histopathological correlations of fecal calprotectin release in colorectal carcinoma

Table 1 Antibodies used for immunohistochemistry

Antibody	Clone	Dilution	Technique
CD 45R0 (DAKO)	UHCL-1	1:1600	ABC
TIA-1 (IMMUNOTECH)	2G9A10F5	1:1000	ABC
CD3 (VENTANA)	2GV6	Pre-diluted	Benchmark XT
CD4 (VENTANA)	SP-35	Pre-diluted	Benchmark XT
CD8 (VENTANA)	SP-57	Pre-diluted	Benchmark XT
CD57 (VENTANA)	NK-1	Pre-diluted	Benchmark XT
Granzyme B (VENTANA)	Polyclonal	Pre-diluted	Benchmark XT

Table 2 Baseline characteristics n (%)

Characteristics		Statistics
Calprotectin		(n = 80)
Demographic data
	Males	46 (57.5)
	Age (yr)	71.1 ± 11.7
Tumor location
	Left	29 (36.2)
	Right	23 (28.7)
	Rectum	26 (32.5)
	Two locations	2 (2.5)
Tumor classification
	T1	5 (6.2)
	T2	12 (15.0)
	T3	49 (61.3)
	T4	13 (16.2)
	N0	44 (55.0)
	N1	16 (20.0)
	N2	18 (22.5)
	M0	71 (88.8)
	M1	8 (10.0)
	G1	1 (1.2)
	G2	57 (71.2)
	G2-3	3 (3.8)
	G3	13 (16.2)
	V0	62 (77.5)
	V1	14 (17.5)
	Pn0	64 (80.0)
	Pn1	12 (15.0)

Data are presented as number of patients (%) and as mean ± SD.

Table 3 Spearman’s rank correlation coefficient between calprotectin and histopathological parameters

	Spearman’s rho	P value
CD45.R.intra	-0.19	0.18
CD45.peri	0.05	0.74
CD3.intra	0.03	0.85
CD3.peri	-0.1	0.47
CD8.intra	-0.04	0.76
CD8.peri	-0.14	0.31
CD4.intra	-0.07	0.64
CD4.peri	-0.06	0.66
TIA1.itra	0.06	0.66
TIR1.peri	0.05	0.71
Granzyma.intra	-0.08	0.57
Granzyma.peri	0.09	0.52
CD57.intra	0.02	0.91
CD57.peri	-0.14	0.31
MPO.intra	0.12	0.4
MPO.peri	0.09	0.55